Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
ANTICOAGULATION TRAINING COURSE
The King’s Thrombosis Centre runs this training course twice a year, which was developed to meet the educational needs of healthcare professionals involved in anticoagulation management. Click here to download an application form and agenda.
EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click the image to access the site.
Latest News
-
Anticoagulation news items. Week commencing 12th August 2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies The Lancet Haematology Study (93 children) found that bodyweight adjusted rivaroxaban appears to be…
-
Anticoagulation news items. Week commencing 5th August 2019
NIHR Signal: Reminders to assess clotting risk increase the use of preventive measures National Institute for Health Research Expert commentary is provided for a review of 13 RCTs (n=35,997) which…
-
Anticoagulation news items. Week commencing 29th July 2019
Revised SPC: Xarelto (rivaroxaban) tablets electronic Medicines compendium SPC now advises that rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement as the…
